These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 10059)

  • 1. Behavioral studies on the enantiomers of butaclamol demonstrating absolute optical specificity for neuroleptic activity.
    Voith K; Cummings JR
    Can J Physiol Pharmacol; 1976 Aug; 54(4):551-60. PubMed ID: 10059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The behavioral pharmacology of butaclamol hydrochloride (AY-23,028), a new potent neuroleptic drug.
    Voith K; Herr F
    Psychopharmacologia; 1975 Apr; 42(1):11-20. PubMed ID: 1171496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroleptics related to butaclamol. Synthesis and some psychopharmacological effects of a series of 3-aryl analogues.
    Voith K; Bruderlein FT; Humber LG
    J Med Chem; 1978 Jul; 21(7):694-8. PubMed ID: 27637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroleptics related to butaclamol. An investigation of the effects of chlorine substituents on the aromatic rings.
    Humber LG; Sideridis N; Asselin AA; Bruderlein FT; Voith K
    J Med Chem; 1978 Dec; 21(12):1225-31. PubMed ID: 31480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mapping the dopamine receptor. 1. Features derived from modifications in ring E of the neuroleptic butaclamol.
    Humber LG; Bruderlein FT; Philipp AH; Götz M
    J Med Chem; 1979 Jul; 22(7):761-7. PubMed ID: 571916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mapping the dopamine receptor. 2. Features derived from modifications in the rings A/B region of the neuroleptic butaclamol.
    Philipp AH; Humber LG; Voith K
    J Med Chem; 1979 Jul; 22(7):768-73. PubMed ID: 571917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Behavioral characteristics of olanzapine: an atypical neuroleptic.
    Fu Y; Zhu ZT; Chen LJ; Yu LP; Jin GZ
    Acta Pharmacol Sin; 2000 Apr; 21(4):329-34. PubMed ID: 11324461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is 3-PPP a potential antipsychotic agent? Evidence from animal behavioral studies.
    Clark D; Carlsson A; Hjorth S; Svensson K; Engel J; Sanchez D
    Eur J Pharmacol; 1982 Sep; 83(1-2):131-4. PubMed ID: 6127226
    [No Abstract]   [Full Text] [Related]  

  • 9. A lever-release version of the conditioned avoidance response paradigm: effects of haloperidol, clozapine, sulpiride, and BMY-14802.
    White IM; Ciancone MT; Haracz JL; Rebec GV
    Pharmacol Biochem Behav; 1992 Jan; 41(1):29-35. PubMed ID: 1347175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of the butaclamol template in a search for antipsychotic agents with lessened side effects.
    Kukla MJ; Bloss JL; Brougham LR
    J Med Chem; 1979 Apr; 22(4):401-6. PubMed ID: 34721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CI-943, a potential antipsychotic agent. I. Preclinical behavioral effects.
    Heffner TG; Downs DA; Meltzer LT; Wiley JN; Williams AE
    J Pharmacol Exp Ther; 1989 Oct; 251(1):105-12. PubMed ID: 2571712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological study of [2-chloro-11-(2-dimethylaminoethoxy) dibenzo[b,f]thiepine] (zotepine), a new neuroleptic drug.
    Uchida S; Honda F; Otsuka M; Satoh Y; Mori J; Ono T; Hitomi M
    Arzneimittelforschung; 1979; 29(10):1588-94. PubMed ID: 42413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological studies on timiperone, a new neuroleptic drug. Part I: Behavior effects.
    Yamasaki T; Kojima H; Sakurai T; Kasahara A; Watanabe S; Fujiwara M; Ueki S
    Arzneimittelforschung; 1981; 31(4):701-7. PubMed ID: 6113833
    [No Abstract]   [Full Text] [Related]  

  • 14. On the mode of action of 3-(3-hydroxyphenyl)-N-n-propylpiperidine, 3-PPP, and its enantiomers. With particular reference to dopaminergic mechanisms in the central nervous system.
    Hjorth S
    Acta Physiol Scand Suppl; 1983; 517():1-52. PubMed ID: 6138921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In rats, the behavioral profile of CCK-8 related peptides resembles that of antipsychotic agents.
    Van Ree JM; Gaffori O; De Wied D
    Eur J Pharmacol; 1983 Sep; 93(1-2):63-78. PubMed ID: 6138272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pharmacological and anatomical substrates of the amphetamine response in the rat.
    Creese I; Iversen SD
    Brain Res; 1975 Jan; 83(3):419-36. PubMed ID: 234270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anorexic and behavioural effects of a new imidazo-isoindole derivative (mazindol) in comparison with d-amphetamine in the rat.
    Babbini M; Gaiardi M; Bartoletti M
    Pharmacology; 1977; 15(1):46-56. PubMed ID: 557207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroleptic agents of the benzocycloheptapyridoisoquinoline series. 1. Syntheses and stereochemical and structural requirements for activity of butaclamol and related compounds.
    Bruderlein FT; Humber LG
    J Med Chem; 1975 Feb; 18(2):185-8. PubMed ID: 1168258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alterations in amphetamine stereotypy following acute lesions of substantia nigra.
    Gonzalez LP
    Life Sci; 1987 Mar; 40(9):899-908. PubMed ID: 3546989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of butaclamol and of other neuroleptic agents on the apomorphine-elicited inhibition of synaptosomal tyrosine hydroxylase activity.
    Bronaugh RL; Tabak J; Ohashi T; Goldstein M
    Psychopharmacol Commun; 1975; 1(5):501-10. PubMed ID: 7003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.